Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)¹, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States.

The appointment was conferred by Deputy Prime Minister and Foreign Minister Antonio Tajani and transmitted by the Ambassador of Italy to the United States, Marco Peronaci. The Board of Guarantors is composed of twelve members: six appointed by the Italian Government and six by Columbia University.

The Board of Guarantors plays an important role in supporting the activities of the Academy and its Director, helping preserve the institution's high standards of academic and cultural excellence and strengthening its ties with Italian institutions. Founded in 1991 with the support of the Italian Republic, the Italian Academy for Advanced Studies in America is an interdisciplinary research center at Columbia University dedicated to fostering dialogue and collaboration between scholars, artists, and intellectuals from Italy and around the world. Through fellowships, research programs, conferences, and public events, the Academy promotes the study and dissemination of Italian culture and thought while encouraging transatlantic intellectual exchange.

"I am deeply honored by this appointment to the Board of Guarantors of the Italian Academy at Columbia University, an institution that plays a vital role in strengthening intellectual and cultural ties between Italy and the United States," said Pierluigi Paracchi. "As a CEO of the Company and Chairman of Fondazione Praexidia, I have been working to promote Italy's strategic technological sectors — from defense and aerospace to biotechnology. I believe that connecting science, industry, and international collaboration is critical to a country's long-term competitiveness, and that this perspective aligns closely with the Academy's mission and can contribute to deepening dialogue between the Italian scientific and cultural ecosystem and leading academic institutions in the United States."

For additional information on the governance of the Italian Academy, please visit: https://italianacademy.columbia.edu/content/governance-academy

About: Genenta Science (Nasdaq: GNTA), which will be renamed as Saentra Forge (Nasdaq: SAEN, pending effectiveness), will be a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity.

Forward-Looking Statements. Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech, the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM or any related studies, as well as Genenta’s ability to establish partnerships and fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024, and Genenta's material disclosures on Form 6-K dated January 26, 2026, both filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.

Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
e.mail: tiziana.pollio@genenta.com

^{___________________
1} The new corporate name and the new Nasdaq ticker symbol will become effective upon official Notary filing in Italy, presuming approval by its shareholders at a Shareholders’ Meeting scheduled for March 25-26, 2026.